A Major Scientific Breakthrough from the Abivax Joint Laboratory and the Tazi Team at IGMM
On July 23, 2025, the French biotech company Abivax announced highly positive Phase 3 results from two clinical trials evaluating the efficacy of its drug obefazimod for the treatment of ulcerative colitis (UC). This innovative therapy targets microRNA miR-124 — a novel mechanism discovered through fundamental research by Professor Jamal Tazi’s team at IGMM (CNRS / University of Montpellier), in … Continue reading A Major Scientific Breakthrough from the Abivax Joint Laboratory and the Tazi Team at IGMM


